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Background: People with Parkinson’s disease (PD) experience not only motor problems
but also non-motor problems that seriously impede their daily functioning and quality
of life. The current pharmacologic treatment of PD is symptomatic, and alternative
rehabilitation treatments, which preferably also have a disease-modifying effect and
promote neuroplasticity, are needed. Recent studies suggest that high-intensity interval
training (HIIT) is promising for promoting neuroplasticity in human PD, with short
training time and reduced burden. Biomarkers for neuroplasticity such as brain-derived
neurotrophic factor (BDNF) and neurodegeneration (including neurofilament NfL and
α-synuclein) may play a role, but their response to HIIT is not well-investigated.
Objectives: The aims of this study were (1) to study the effects of 4 weeks
of HIIT compared with 4 weeks of continuous aerobic exercise on motor and
non-motor outcomes of PD and (2) to investigate the association between HIIT,
motor/non-motor performances changes, and blood biomarker levels for neuroplasticity
and neurodegeneration.
Study Design: Single-subject research design with alternating treatment setup
(ABACA) and frequent repeated measurements was used. Each participant received
different intervention conditions (B/C) interspersed with baseline periods (A, i.e., ABACA
or ACABA), and frequent repeated assessment of outcome measures is done to
quantify within-subject, individual response patterns with sufficient power for data
analysis. Blood samples were collected once a week in the baseline and training
phases (A1 and B/C) and once every 2 weeks in the washout phases (A2 and A3).
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Intervention: Four subjects with PD on stable dopaminergic medication, two in Hoehn–
Yahr stage 1–2, and two in Hoehn–Yahr stage 2.5–3 followed an ABACA or ACABA
schedule, consisting of blocks with 30-min sessions of “B” (HIIT) or 50-min sessions of
“C” [continuous aerobic exercise (CAE)] 3×/week for 4 weeks, separated by baseline “A”
periods of 8 weeks for a total duration of 28 weeks.
Outcome Measures: Outcome measures include disease status [Movement Disorder
Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-
UPDRS)], blood biomarkers (BDNF, Nfl, and α-synuclein), measures for functional mobility
(including an activity tracker), and activities of daily living, as well as cognition, mood,
biorhythm (sleeping problems), and quality of life.
Data Analysis: Visual analysis of trends in level, slope, and variability in response
patterns was carried out, confirmed by longitudinal regression analysis with phase
(ABACA) as the independent variable.
Keywords: Parkinson’s disease, high intensity (strenuous) exercise, neuroplastic changes, BDNF, NFL, synuclein
alpha
INTRODUCTION
Parkinson’s disease (PD) is a complex, chronic, highly
disabling progressive neurodegenerative movement disorder,
characterized by the loss of dopamine neurons in the substantia
nigra (1). The disease is characterized by motor (e.g., tremor,
gait disturbance, bradykinesia, and falls) and also non-
motor (e.g., depression, reduced cognitive performance, and
biorhythm/sleep) symptoms (2). To date, there is no cure.
Current treatment paradigms are mainly aimed at alleviating
motor and psychiatric features but do not consider individual
differences in treatment response or molecular profile. Moreover,
several motor (e.g., gait disturbances and balance disturbances)
and non-motor (e.g., mood disturbances, cognitive functioning,
and sleep problems) features respond insufficiently to current
pharmacological treatments; and unfortunately, we do not
have rehabilitative strategies that halt or slow down disease
progression (2, 3). Frequent physical exercise training is
increasingly recognized as an effective therapy for PD and
other neurodegenerative diseases that may even exert disease-
modifying influences through neuroplastic mechanisms
(4, 5).
Aerobic and/or progressive resistance exercise based on
the American College of Sports Medicine recommendation
of 3×/week, 30–60 min/session for at least 12 weeks
demonstrate long-term (>12 weeks) improvements in both
motor performance [e.g., walking speed, aerobic capacity, and
lower-limb muscle strength; (6)] and cognitive performance
(attention and executive functioning) in PD patients (3, 7).
Shorter-lasting aerobic exercise programs (3×/week, 30–60
min/session for 4 weeks) may also show improvements in motor
performance (e.g., walking speed and aerobic capacity), though
the long-term effects of short-term aerobic exercise are less
consistent (4).
Physical training studies show promising results in terms
of exercise-induced neuroplasticity, at both symptom and
molecular levels in human and animal models of exercise and
PD (8). For example, voluntary treadmill running in mice
for 40 min/day, 5 days/week for 18 weeks improved motor
coordination and aerobic capacity and reduced nigrostriatal
neuronal loss (9). The improvements were associated with
increased levels of BDNF in the substantia nigra and striatum.
A recent review and a meta-analysis showed that HIIT has
acute and long-term effects on serum BDNF levels (10, 11).
Several studies suggest that serum BDNF concentration levels
are reduced in PD patients [for example, Frazzitta et al. (12)].
Low BDNF is associated not only with cognitive impairments
in PD patients (13) but also with mood disturbances (14).
Biomarkers for neuroplasticity, such as BDNF, and biomarkers
for (synaptic) neurodegeneration (including neurofilament NfL
and α-synuclein) are, respectively, decreased and increased
in PD patients compared with age-matched controls (15–17).
Studies suggest intensive physical training to be promising
for modulating these biomarkers in people with PD (11,
12). BDNF has shown to respond well to intensive physical
training; for serum NfL and α-synuclein, this has not yet been
properly investigated.
A promising, time-efficient, and highly effective physical
exercise strategy is “high-intensity interval training” (HIIT),
which only recently is being explored in clinical research
(18). HIIT encompasses several intervals of short-lasting, high-
intensity bouts alternated with low-intensity bouts, that has
shown to match or even surpass the cardiovascular responses to
moderate continuous aerobic exercise (CAE) (19). This increased
efficiency is achieved in a shorter period of total training time,
which may enhance the motivation of PD patients and help
promote adopting a more active lifestyle (19). For example, HIIT
for three 40-min sessions per week for 8 weeks has been suggested
to evoke enhanced adaptive aerobic capacity (e.g., increased
aerobic capacity) as well as increased cognitive performance, as
compared with CAE in healthy older adults and older adults
with mild cognitive impairment (19). Similar results have been
Frontiers in Neurology | www.frontiersin.org 2 October 2020 | Volume 11 | Article 569880
van Wegen et al. HIIT in Parkinson’s Disease
found for adult type 2 diabetes mellitus patients (18) and adult
cardiovascular patients (4).
Only a few studies to date have investigated the effect
of HIIT on motor and non-motor outcomes in PD. High
feasibility of HIIT in PD was recently demonstrated (20):
participants were able to be complete 45min of HIIT three
times a week for 12 weeks without intervention-related dropouts
and >80% compliance. Group session HIIT consisted of an
exercise gym circuit designed to elicit a physiological response
indicative of high-intensity exercise (≥85% HRmax). Fernandes
et al. (21) performed a pilot randomized controlled single-blind
trial to study the effect of 12 weeks of HIIT vs. moderate-
intensity continuous exercise (MICE) training in PD. They
enrolled 20 participants, with Hoehn–Yahr stage 1–3, who
performed walking/jogging training three times per week for 12
weeks. The HIIT protocol consisted of a 1-min walking/jogging
bout at rating of perceived exertion (Borg scale RPE) scale
15–17 level alternated with 2min of walking at 9–11 level
of RPE during a 25-min session. MICE training consisted
of 26min of walking/jogging at 11–14 level of RPE. HIIT
improved 6-min walk test distance and increased endothelial
reactivity (a marker for increased blood flow). These values
did not change with MICE. They did not measure non-
motor outcomes. O’Callaghan et al. (22) entered the sample
by Harvey et al. into a new comparison in a 12-week pilot
study of HIIT or MICE. Their study supports the feasibility
of HIIT in PD and found that HIIT increased circulating
serum brain-derived neurotrophic factor (BDNF), a protein
that may play a key role in neuroplasticity maintaining or
improving brain functions (10). BDNF levels were higher after
HIIT compared with continuous moderate-intensity aerobic
training (22).
The combined evidence of animal and human studies
suggests that motor performance, cognitive performance, and
mood in PD are related and that biomarkers for neuroplasticity
and neurodegeneration are associated with both motor
and non-motor features. This underpins the importance of
disease-modifying treatment in PD including aerobic and/or
progressive resistance exercise as adjuncts to pharmacological
treatment for the control of motor and non-motor features. As
such, determining the optimal type and dosage of exercise
interventions to obtain these neuroplastic effects is an
important focus of current neurorehabilitation research
in PD (8, 23).
Researchers argue that the heterogeneity of patient
populations and use of classic intervention study design
are major confounding factors in making progress toward
determining optimal type and dosage of exercise interventions
(24). Within-participant research designs with frequently
repeated measurements (i.e., single case experimental designs)
may be more suitable than group studies to capture individual
recovery patterns. This design allows for more continuous
repeated measures of the target outcomes, at baseline, during,
and after the intervention period (25). Incorporation of many
repeated measures allows a detailed analysis of individual
responses with adequate power. No single study has compared
the effects of HIIT with CAE on changes in motor performance,
cognitive abilities, mood disturbances, and biorhythms/sleep in
people with PD and whether improvements are associated with
quantitative changes in blood-based biomarkers (BDNF, NfL,
and α-synuclein).
Therefore, the first objective of this pilot study is to explore
the response patterns of motor and non-motor performance
and serum biomarker levels to 4 weeks of HIIT compared with
4 weeks of traditional moderate CAE in four single subjects
with PD. The second objective is to explore the associations
between changes in motor and non-motor outcome measures
and serum neuroplasticity and neurodegeneration biomarkers
for both exercise conditions.
Our central hypothesis is that HIIT is more effective at
improving motor performance, cognition, mood, and sleep as
well as increasing concentration of BDNF and decreasing NfL
and α-synuclein levels thanmoderate-intensity CAE. In addition,
we expect that HIIT-induced changes in serum BDNF, NfL, and
α-synuclein protein levels are associated with changes in motor
and non-motor performance of PD patients.
METHODS
Study Design
We will use a single-subject alternating treatment approach
with A1-B-A2-C-A3 or A1-C-A2-B-A3 design to study the
effects of HIIT on motor and non-motor performance and
neuroplasticity and neurodegeneration biomarkers such that
subjects will perform both the HIIT (B-phase) and the moderate
CAE training (C-phase) for 4 weeks. After a baseline (A1)
period of 4 weeks, the first intervention period of 4 weeks will
take place (B or C), followed by a washout period of 8 weeks
without an intervention (A2), the second intervention period
of 4 weeks (B or C), and finally a third washout period of 8
weeks (A3). Each patient therefore experiences the full set of
treatment approaches. The order of interventions B and C will be
randomized for each participant (i.e., ABACA or ACABA, two of
each, four participants total) using a random sequence generator.
Assessment will be done by Good Clinical Practice (GCP)-trained
blinded assessors.
Study Population
This exploratory pilot study aims to recruit a convenience
sample of four subjects with confirmed idiopathic PD on stable
dopaminergic medication via the outpatient clinic for movement
disorders at AmsterdamUMC, Vrije Universiteit Medical Center,
Amsterdam, the Netherlands. Patients are asked in the study
information letter to maintain a stable medication schedule
throughout the study, unless the treating neurologist deems it
medically necessary to adapt drug treatment. When applicable,
this will be recorded and taken into account in the analysis.
The study was approved by the Medical Ethics Committee
of Amsterdam UMC, Vrije Universiteit Medical Center (nr.
2029.083). The study will be conducted in compliance with the
Declaration of Helsinki.
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Inclusion and Exclusion Criteria
Inclusion criteria are (1) diagnosis of idiopathic PD according
to UK Brain Bank criteria (26); (2) Hoehn–Yahr stage 1
(n = 2 patients) and 2.5–3 (n = 2 patients) as confirmed
by a trained assessor; (3) age between 55 and 80 years;
(4) sufficient cognition to comprehend training instruction
[Montreal Cognitive Assessment (MoCA) score > 21]; and (5)
able to provide written informed consent. Exclusion criteria
are (1) history of neurologic deficits other than PD; (2)
severe fluctuating responses to dopaminergic medication; (3)
psychiatric, musculoskeletal, or metabolic disorders prohibiting
participation in intensive exercise training; (4) cardiovascular
disorders or cardiac risk prohibiting participation in intensive
exercise training as assessed by Lausanne Questionnaire [>2
risk items scored “yes”; Bille et al. (27)]; and (5) participation
in a professionally supervised high-intensity therapy/exercise
program to improve fitness in the 2 months before inclusion.
Measurement Procedures and Training
All testing and training will be performed in the “on”
state, ∼1–1.5 h after medication intake. Prior to allocation,
subjects will complete baseline testing for demographics and
for motor and non-motor symptoms (Table 1). Assessment
of demographics and baseline characteristics will include, age,
height, weight, sex, disease duration, Movement Disorder
Society-sponsored revision of the Unified Parkinson’s Disease
Rating Scale (MDS-UPDRS I to IV), Hoehn–Yahr stage and
LEDD (levodopa equivalent daily dose), medication schedule
and usage (dopaminergic, psychopharmacological, and any other
medications), and number of falls in past month.
VO2-Max Test Procedure
At the end of the A1 phase, subjects will perform a VO2-
Max test to determine individual training load, as described by
Mavromatti et al. (28). In brief, the exercise test will be conducted
on an electronically braked cycle ergometer (Excalibur Sport,
Lode, the Netherlands), integrated with a cardiopulmonary-
monitoring system that controls the work rate protocol on the
ergometer and records breath-by-breath measurements of VO2,
VCO2, ventilation, and heart rate (Cosmed Benelux BV, the
Netherlands) throughout the test. Handlebars and saddle of the
cycle ergometer will be adjusted to match each participant’s
anthropometrics. The work rate protocol consists of 2-min
steps starting with unloaded cycling and then increasing to
50W, and thereafter increasing in steps of 25W. While the
ergometer maintains a constant workload, independent of
cadence, participants are instructed to aim for cadence of ∼60–
80 rpm. At the end of each step, participants are asked to
rate their level of exertion (rating of perceive exertion) using
the Borg RPE 10-point category ratio scale (Borg CR10 scale,
“0” to “10”) (29). Participants are verbally encouraged to carry
on for as long as possible. The exercise test is terminated by
voluntary exhaustion, by a cadence<45 rpm or for safety reasons,
compliant with the American College of Sports Medicine’s
guidelines for clinical exercise testing (30). Subjects are asked to
abstain from exercise and consumption of alcohol or caffeine 12 h
prior to testing.
Outcome Measures
Outcome measures are chosen based on recommendations
by the Movement Disorders Society (31), the 2014 European
guideline of physical therapy for PD (32), and recommendations
by the members of the project team, including several PD
patients. Table 1 shows the timeline and assessment schedule
for demographics and all outcome parameters. Demographics
include age, sex, disease duration, Hoehn–Yahr stage, medication
schedule and dosage, and MoCA score.
The primary study parameter is disease severity measured
every 4 weeks during baseline A1 and A2 and intervention and
two times during baseline A3 with the MDS-UPDRS part III
(motor examination) during on-state (33).
Secondary outcome parameters were pre–post intervention
outcome measures will be administered before and after each
study phase; and disease status with MDS-UPDRS 1, II,
and IV (33). Cognition will be evaluated with the MoCA
(34), the Stroop test (35), and the Trail Making Test for
executive function [TMT; Olchik et al. (36)] and the PD
Cognitive Functioning Rating Scale (PD-CFRS) (37). Activities
of daily living and quality of life were assessed with self-
report questionnaires: the Nottingham Extended ADL index
(NEAI) (38) and the Parkinson Disease Questionnaire (PDQ-
8) (39). Mood and sleep will be assessed using the Beck
Depression Inventory questionnaire (31) and the Scopa Sleep
scale (40), respectively.
Weekly outcomes are motor performance, namely, the 10-
meter walk test (41), the Timed “Up-and-Go” test (TUG) (42),
and the one-leg stance test (43). In addition, daily physical
activity with a wrist-worn activity tracker will be recorded
throughout the study. For weekly self-report outcomes, we will
use Ecological Momentary Assessment methodology (44), asking
frequent (weekly in baseline phases, three times a week in
intervention phases), short online survey questions about non-
motor functions using Castor EDC (45): Mood will be assessed
with a visual analog scale (VAS) score rating: “Can you rate
your current mood on a scale from “1” to “10”?” (a score of “1”
represents “very sad”; a score of “10” represents “very happy”).
Sleep performance will be assessed with a VAS score rating: “Can
you rate howwell you slept last night on a scale from “1” to “10”?”
(A score of “1” represents “very bad”; a score of “10” represents
“very good”). Cognitive function will be assessed with a VAS score
for “ability to concentrate”: “Can you rate well you are able to
concentrate on daily tasks on a scale from “1” to “10”?” (a score of
“1” represents “very bad”; a score of “10” represents “very good”).
In addition, we will ask the subjects to keep a logbook of their
attended sessions and perceived effort (RPE).
Blood samples (for serum BDNF, NfL, and α-synuclein) will
be collected by a trained nurse once a week in the baseline
and training phases (A1 and B/C). Blood draw frequency is
decreased to once every 2 weeks in the washout phases (A2 and
A3) to reduce patient burden. Twenty-milliliter blood samples
will be taken from the antecubital vein at rest in the morning
hours between 08:00 and 10:00 in the fasting state. We will use
anticoagulant-free tubes, which be placed on ice (−80◦C) until
further analysis. BDNF concentration will be measured with a
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TABLE 1 | Assessment schedule for outcomes across the 28-week study period.
Schedule
Phase Baseline A1 Intervention B/C
Week 1 2 3 4 1 2 3 4
Session s1 s2 s3 s1 s2 s3 s1 s2 s3 s1 s2 s3 s1 s2 s3 s1 s2 s3 s1 s2 s3 s1 s2 s3
Tests Cardiac Screening x
Demographics x
VO2 test x
Motor UPDRSI-IV x x
TUG x x x x x
10m walk x x x x x x x x
one-leg-stance x x x x x x x x
Cognition MoCa x
Stroop test x x
TMT x x
PD-CFRS x x
VAS-concentration x x x x x x x x x x x x x x x x
Mood BDI x x
VAS-mood x x x x x x x x x x x x x x x x
Sleep Scopa sleep x x
VAS-sleep x x x x x x x x x x x x x x x x
ADL NEAI x x
QoL PDQ-8 x x
Blood BDNF/NfL, α-syn x x x x x x x x
Phase Baseline A2 Intervention C/B
Week 1 2 3 4 5 6 7 8 1 2 3 4




Motor UPDRSI-IV x x
TUG x x x x x
10m walk x x x x x x x x
one-leg-stance x x x x x x x x
Cognition MoCa x
Stroop test x x
TMT x x
PD-CFRS x x
VAS-concentration x x x x x x x x x x x x x x x x x x x x
Mood BDI x x
VAS-mood x x x x x x x x x x x x x x x x x x x x
Sleep Scopa Sleep x x
VAS-sleep x x x x x x x x x x x x x x x x x x x x
ADL NEAI x x x
QoL PDQ-8 x x x
Blood BDNF/NfL, α-syn x x x x x x x x
(Continued)
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TABLE 1 | Continued
Phase Baseline A3
Week 1 2 3 4 5 6 7 8




Motor UPDRSI-IV x x
TUG x x x x x
10m walk x x x x x
one-leg-stance x x x x x
Cognition MoCa x
Stroop test x x
TMT x x
PD-CFRS x x
VAS-concentration x x x x x x x x
Mood BDI x x
VAS-mood x x x x x x x x
Sleep Scopa Sleep x x
VAS-sleep x x x x x x x x
ADL NEAI x x x
QoL PDQ-8 x x x
Blood BDNF/NfL, α-syn x x x x x
Planning of baseline (A1, A2, and A3), intervention (B and C), and measurements (crosses indicate time movements). Pre–post phase measurements will be performed before and after
both baseline and both intervention phases.
UPDRS, MDS-Unified Parkinson’s Disease Rating Scale; MoCa, Montreal Cognitive Assessment; PD-CFRS, PD Cognitive Functioning Rating Scale; Stroop, Stroop test; VAS, visual
analog scale; BDI, Beck Depression Inventory; ADL, activities of daily living; Scopa Sleep, Sleep scale from Scopa; NEAI, Nottingham Extended ADL index; QoL, quality of Life; PDQ-8,
Parkinson’s Disease Questionnaire; BDNF, brain-derived neurotrophic factor; NfL, neurofilament light; α-syn, alpha synuclein.
commercially available and in-house validated kit (Quanterix
Simoa). Serum NfL and α-synuclein concentrations will be
measured using an in-house developed Homebrew Simoa assay
(17, 46).
Training Protocol
Subjects will perform HIIT or moderate CAE on a stationary
bicycle (Lode Corival, Lode Inc.) 3×/week for two periods
of 4 weeks in a group of four subjects (Figure 1). The
order of the intervention phases will be randomized.
Training will take place on Mondays, Wednesdays, and
Fridays, to allow for sufficient recovery periods between
training sessions.
Each HIIT session is about 30min of interval training, starting
with a 5min of warm-up at 25–35% W-max. Subsequently, six
to eight blocks of HIIT will be performed, alternating 45 s at
>85% VO2-max, with 90 s at 30–40% W-max. After the interval
block, 5min of cooling-down will be performed at 20–35% W-
max.Workload will be progressively adapted using a fixed weekly
schedule or upon therapist decision by adding intervals at the end
of the sessions.
Each CAE session is about 50min of continuous training
at a preset workload of about 55% W-max. Workload will be
progressively adapted after every week by reducing rest time,
based on a fixed schedule or upon therapist decision. A trained
physiotherapist-supervisor, assisted by GCP-trained interns from
the Faculty of Human Movement Sciences will assist the
subjects with water, music, and motivational encouragements.
Throughout the study, patients are asked to maintain their
regular medication.
The Ecological Momentary Assessments taken weekly (A
phases) or every other day (B/C phases) using the online survey
throughout the study period will act automatically as reminders
and will help with compliance to training and assessments. We
will comply with consensus recommendations of Slade et al. (47)
regarding reporting on exercise interventions.
Statistical Analysis
Although the protocol specifies primary and secondary study
outcomes, we will assess the results based on a combination of
those parameters.
For example, the primary research parameter that we have
specified is the MDS-UPDRS-III, which is measured before and
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FIGURE 1 | Intensity-work rate plot for CAE and HIIT session. Left: intensity-work rate plot for a 50-min CAE intervention session. Right: intensity-work rate plot for a
30-min HIIT intervention session. CAE training intensity will be at about 55% W-max, HIIT will alternate between training intensity 35% W-max during low-intensity
intervals and >85% W-max at high-intensity intervals. CAE, continuous aerobic exercise; HIIT, high-intensity interval training.
after each phase. If, under the influence of the interventions,
there are improvements within the participants that are greater
than the measurement error of 3.25 points known from the
literature (48), this is a clear indication that the intervention
influences motor function. However, if there is less or no
change in the MDS-UPDRS-III but in one or more other
parameters, this is still informative with regard to the effects
of the different interventions and the underlying mechanisms.
If no change is visible in any parameter under the influence
of the interventions in any participant (through visual analysis
and/or statistical tests), then the conclusion should be that there
is no effect.
Visual inspection is the method of choice for single-subject
research designs (SSRDs) (24). We will inspect, analyze, and
describe the changes across the baseline and intervention phases
(phase mean level and data spread), and we will compare
the trend (slope) of scores with the baseline mean levels
and variability (standard deviations) on outcomes for each
intervention strategy and each patient. Longitudinal regression
analysis with “phase” (i.e., condition) as the independent variable
will be used for further confirmation (α = 0.05).
We will not explicitly test for group differences between
patients in Hoehn–Yahr stage 1–2 or for patients in Hoehn–Yahr
stage 2.5–3, but we will get insights on the direction of effects and
effect sizes in the intervention phases compared with the baseline
phases, which we will report descriptively for both participants in
both subgroups.
The association between biomarkers and symptom changes
will be quantified by Pearson correlation coefficients
and corrected for age, between changes in BDNF, α-
synuclein, and Nfl and change scores on primary and
secondary parameters.
DISCUSSION
Accumulating scientific evidence supports the use of physical
rehabilitation training and exercise as an effective non-
pharmacologic therapy to improve motor symptoms, problems
with mobility and gait (49, 50), and non-motor features,
including mood, cognition, and sleep [for review, see Reynolds
et al. (51)] for patients at all stages of PD. Intensive exercise
may even induce neuroplastic disease-attenuating effects via
endogenous production of neurotrophic factors, including
BDNF (4, 5, 52, 53).
There has been considerable progress in the area of physical
training-induced neuroplasticity effects in PD (11, 54, 55),
though our understanding is far from complete. Studies reported
that PD patient show increased serum NfL protein levels (17)
compared to age-matched healthy controls. NfL is a marker
for axonal damage and related to cortical degeneration in PD
(15). As we have stated earlier, the effect of physical exercise
training on NfL serum protein levels in early or late stage PD is
currently unknown.
Neurotrophic factors, including BDNF, are soluble
endogenously produced polypeptides that are involved in
the development, growth, functioning, and regulation of
neurons and neuron-supporting cells. Studies indicate that
continuous high-intensity training, moderate-intensity CAE,
or low-intensity exercise enhances serum and plasma BDNF
levels (12, 22, 52, 56). A recent meta-analysis showed cumulative
evidence of physical exercise induced improved serum BDNF
protein levels in PD (11). It is plausible that besides activation
of the neurotrophic pathway (10), physical training increases
blood flux into basal ganglia (57) and that this increased flux
may stimulate vascular endothelial cells to secrete BDNF as a
response to blood shear stress in the vessels (58). BDNF also has
known cytoprotective effects on the striatum (59).
Reduced aerobic and anaerobic capacity are common in
the elderly and especially in PD patients, though the rate
of capacity reduction can be decreased by adopting a more
active physical lifestyle (1). The experimental intervention in
this study, HIIT, has already been used in sports science
to improve both aerobic and anaerobic capacity (18); and
preliminary studies are emerging in the field of PD. It is
plausible that HIIT can be a time-efficient type of exercise
that integrates both aerobic and anaerobic exercise, thereby
enhancing the motivation of PD patients to comply with the
intervention and in the long run promote a more active
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lifestyle. To our knowledge, we are the first to explore the
within-subjects responses of blood biomarkers with weekly
repeated measurements over multiple weeks (during baseline,
washout, and intervention periods) for the two different
exercise conditions. The design of the study allows for careful
individual exploration of the response patterns of different
exercise strategies on both symptoms and biomarkers. The
advantage is that a small sample is enough to get important
new knowledge, which will facilitate future well-powered
clinical trials.
This study primarily explores whether HIIT is more effective
at improving motor and cognitive performance than moderate
CAE. If our hypothesis that HIIT is more effective than
moderate CAE is correct, future HIIT studies in PD patients
can add other treatment types, such as cognitive stimulation. For
example, the Park-in-Shape study (60) investigated the feasibility
of adding “exergaming” elements to improve adherence.
Furthermore, a recent publication of a large observational
study in PD patients in the Netherlands highlights the
cost-effectiveness of specialized goal-based physical activity
therapy by reducing both health-care cost and disease-related
complications (61), which should be explored in future studies by
combining HIIT with exercise goals beyond mere completion of
the protocol.
To increase the societal relevance and impact of the
current study protocol, two Parkinson patients who
were consulted during the design process of this study
expressed optimism about the procedures presented in this
protocol. They also acknowledged the need for a better
understanding of individual neural response patterns to different
exercise intensities.
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